Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsViva Health Benlysta Coverage Prior Auth | OpenPay…
    Ask Trek AI about this page
    CurrentViva Health PlanPolicy IC-P0017

    Benlysta (belimumab) (Intravenous)

    Customize your policy alerts

    Sign up for vivahealthplan Policy IC-P0017 alerts

    Get alerted when Policy IC-P0017 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization, dosing, medical necessity, and billing requirements for intravenous Benlysta (belimumab) for members with active systemic lupus erythematosus or lupus nephritis under commercial coverage.

    Policy Summary
    PayerViva Health Plan
    PolicyBenlysta (belimumab) (Intravenous)
    Policy CodePolicy IC-P0017
    Change TypeNo material clinical or coverage changes
    Effective DateN/A
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation that the member meets the applicable indication, age, specialist, safety, and therapy requirements for prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsInitial authorization validity
    12 monthsRenewal authorization interval
    116 unitsLoading dose maximum
    116 units/28 daysMaintenance dose maximum
    10 mg/kg IV

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy dosing

    Coverage Criteria

    Continuation therapy

    Renewal is covered when all renewal requirements are met.

    Renewal therapy

    • The member continues to meet the universal criteria identified in the initial criteria.
    • The member continues to meet applicable indication-specific concomitant-therapy requirements identified in the initial criteria, excluding prerequisite therapy.
    • The member has had clinical benefit with Benlysta.

    Coverage is excluded for members with severe active central nervous system (CNS) lupus.

    Coverage is excluded when the member has any FDA-labeled contraindication to Benlysta.

    Billing and Coding

    HCPCS CodeHCPCSCovered
    J0490Injection, belimumab, 10 mg; 1 billable unit = 10 mg
    NDC(s)NDCCovered
    49401-0101-xxBenlysta 120 mg/5 mL single-dose vial for injection
    49401-0102-xxBenlysta 400 mg/20 mL single-dose vial for injection
    Covered Diagnosis CodesICD-10Covered
    M32.10Systemic lupus erythematosus organ or system involvement unspecified
    M32.11Endocarditis in systemic lupus erythematosus
    M32.12Pericarditis in systemic lupus erythematosus
    M32.13Lung involvement in systemic lupus erythematosus
    M32.14Glomerular disease in systemic lupus erythematosus
    M32.15Tubulo-interstitial nephropathy in systemic lupus erythematosus
    M32.19Other organ or system involvement in systemic lupus erythematosus
    M32.8Other forms of systemic lupus erythematosus
    M32.9Systemic lupus erythematosus, unspecified
    Covered Diagnosis CodesICD-10Covered
    M32.10Systemic lupus erythematosus organ or system involvement unspecified
    M32.11Endocarditis in systemic lupus erythematosus
    M32.12Pericarditis in systemic lupus erythematosus
    M32.13Lung involvement in systemic lupus erythematosus
    M32.14Glomerular disease in systemic lupus erythematosus
    M32.15Tubulo-interstitial nephropathy in systemic lupus erythematosus
    M32.19Other organ or system involvement in systemic lupus erythematosus
    M32.8Other forms of systemic lupus erythematosus
    M32.9Systemic lupus erythematosus, unspecified
    Loading-dose maximum
    Dose typeLoading dose
    Maximum116 billable HCPCS units
    Administration scheduleOn days 1, 15, and 29
    Maintenance-dose maximum
    Dose typeMaintenance dose
    Maximum116 billable HCPCS units
    Administration intervalPer 28 days

    Authorization and Documentation Requirements

    Prior Authorization

    Authorization Duration

    Initial prior authorization is valid for 12 months (365 days). Renewal may be authorized for additional 12-month (365-day) intervals when renewal criteria are met.

    • Initial authorization: 12 months (365 days)
    • Renewal authorization: every 12 months (365 days)
    Prior Authorization

    Initial Authorization Requirements

    For initial approval, document an FDA-labeled indication for Benlysta and satisfy the applicable age, specialist, safety, indication-specific therapy, and concomitant-therapy requirements below.

    • Active SLE without active lupus nephritis, or active lupus nephritis
    • Member age must be within FDA labeling for the requested indication, or submitted evidence must support use at the member’s age
    • Prescriber must be a specialist in the diagnosis area or document specialist consultation

    Unsupported block type: documentation

    Policy Background

    Benlysta (belimumab) is an intravenous biologic used with standard therapy for active systemic lupus erythematosus (SLE) and active lupus nephritis. The policy distinguishes active SLE without active lupus nephritis from kidney-biopsy-confirmed Class III, IV, or V lupus nephritis and requires appropriate background therapy.

    Definitions

    SLE without active lupus nephritis
    ConditionActive systemic lupus erythematosus (SLE)
    Lupus nephritis statusWithout active lupus nephritis (LN)
    Therapy contextContinue standard SLE therapy in combination with the requested agent
    Qualifying lupus nephritis
    ConditionActive lupus nephritis
    Confirmation methodConfirmed via kidney biopsy
    Qualifying classesClass III, IV, or V lupus nephritis

    Initial Therapy Criteria

    Initial criteria

    Initial authorization requires an FDA-labeled or otherwise supported indication, appropriate age support, universal criteria, and a qualifying SLE or lupus nephritis pathway.

    Initial Benlysta criteria

    • Age and indication support

      • The member's age is within FDA labeling for the requested indication.
      • There is support for using the requested agent for the member's age and requested indication.

    • Universal criteria

      • The prescriber is a specialist in the area of the member's diagnosis, such as a rheumatologist or nephrologist, or has consulted with a specialist in the area of the member's diagnosis.

    Continuation Therapy Criteria

    Renewal criteria

    Renewal requires continued universal and applicable concomitant-therapy criteria plus clinical benefit.

    Benlysta renewal criteria

    • The member continues to meet the universal criteria identified in the initial criteria.
    • The member continues to meet applicable indication-specific concomitant-therapy requirements identified in the initial criteria, excluding prerequisite therapy.
    • The member has had clinical benefit with Benlysta.

    Step Therapy Requirements

    StepRequired therapyCriteria
    1Hydroxychloroquine plus one corticosteroid or immunosuppressive agent (azathioprine, methotrexate, mycophenolate, or cyclophosphamide)For active SLE without active lupus nephritis, the member must have tried and had an inadequate response, intolerance, or hypersensitivity to hydroxychloroquine and to one corticosteroid or immunosuppressive agent. An applicable FDA-labeled contraindication may substitute for the relevant trial requirement. The member must continue standard SLE therapy with Benlysta.
    StepRequired therapyCriteria
    2Two standard therapy courses before Benlysta is used with LupkynisThe member must have tried and had an inadequate response to two standard therapy courses, then use Benlysta with Lupkynis plus mycophenolate.

    Quantity and Administration Limits

    Benlysta intravenous loading-dose quantity limit
    DrugBenlysta (belimumab) intravenous
    Loading-dose limit116 billable units
    Applicable daysDays 1, 15, and 29
    Benlysta intravenous maintenance-dose quantity limit
    DrugBenlysta (belimumab) intravenous
    Maintenance-dose limit116 billable units
    Applicable intervalPer 28 days
    Policy Summary
    PayerViva Health Plan
    PolicyBenlysta (belimumab) (Intravenous)
    Policy CodePolicy IC-P0017
    Change TypeNo material clinical or coverage changes
    Effective DateN/A
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation that the member meets the applicable indication, age, specialist, safety, and therapy requirements for prior authorization.
    SourceLink
    On This Page
    Coverage CriteriaBilling and CodingAuthorization and Documentation RequirementsPolicy BackgroundDefinitionsInitial Therapy CriteriaContinuation Therapy CriteriaStep Therapy RequirementsQuantity and Administration Limits
    Step Therapy

    SLE Prerequisite Therapy

    For active SLE without active lupus nephritis, document prior hydroxychloroquine therapy and prior treatment with at least one corticosteroid or immunosuppressive agent, unless the applicable FDA-labeled contraindication exception applies.

    • Inadequate response, intolerance, or hypersensitivity to hydroxychloroquine, or an FDA-labeled contraindication to hydroxychloroquine
    • Inadequate response, intolerance, or hypersensitivity to one corticosteroid or immunosuppressive agent—azathioprine, methotrexate, mycophenolate, or cyclophosphamide—or FDA-labeled contraindications to all listed agents
    • Member will continue standard SLE therapy in combination with Benlysta
    Step Therapy

    Lupkynis Sequencing Requirement

    For lupus nephritis, if Benlysta will be used with Lupkynis, document inadequate response to two standard therapy courses before the combination is authorized.

    • Examples of standard courses include corticosteroids plus Benlysta with mycophenolate, azathioprine, or cyclophosphamide; and corticosteroids plus Lupkynis with mycophenolate
    • The planned regimen must use Benlysta with Lupkynis plus mycophenolate
    Documentation Required

    Indication and Specialist Documentation

    The request must identify the diagnosis and requested indication, the member’s age, and the FDA-labeled age basis or supporting evidence for use at that age. Submit prescriber credentials or documentation of consultation with an appropriate specialist, such as a rheumatologist or nephrologist.

    • Requested indication: active SLE without active LN or active LN
    • Member age and FDA-labeled age support
    • Specialist prescriber or specialist consultation documentation
    Documentation Required

    SLE Prerequisite Therapy Documentation

    Submit treatment history showing inadequate response, intolerance, or hypersensitivity to the required prerequisite therapies, or the applicable FDA-labeled contraindication(s).

    • Hydroxychloroquine history or contraindication
    • One corticosteroid or immunosuppressive-agent history or, where applicable, contraindications to all listed agents
    • Document the therapy names, outcomes, intolerance, hypersensitivity, or contraindication rationale
    Documentation Required

    Lupus Nephritis Documentation

    For active lupus nephritis, submit kidney-biopsy documentation confirming Class III, IV, or V lupus nephritis and identify the planned background immunosuppressive regimen.

    • Kidney biopsy must confirm Class III, IV, or V lupus nephritis
    • Background therapy must include an appropriate regimen, such as a corticosteroid plus mycophenolate, azathioprine, or cyclophosphamide
    Documentation Required

    Lupkynis Combination Documentation

    When Benlysta is requested with Lupkynis, document two prior standard therapy courses with inadequate response and confirm the planned combination of Benlysta, Lupkynis, and mycophenolate.

    • Submit the two prior standard-course regimens and treatment outcomes
    • Confirm planned Benlysta plus Lupkynis plus mycophenolate therapy
    Documentation Required

    Combination Therapy Evidence

    Benlysta may be used with another immunomodulatory agent only when the prescribing information does not limit the combination and supporting evidence is submitted.

    • Submit prescribing-information support showing combination compatibility
    • Submit clinical-trial, phase III study, or guideline support for the combination therapy
    Documentation Required

    Renewal Documentation

    For renewal, submit evidence that the member continues to meet the applicable universal and concomitant-therapy criteria and has experienced clinical benefit with Benlysta.

    • Document ongoing eligibility and required concomitant therapy
    • Document clinical response or other clinical benefit attributable to Benlysta
    Billing Rule

    Medicare Policy Compliance

    For Medicare members, apply the Medicare Benefit Policy Manual requirements for outpatient Part B drugs and any applicable NCDs, LCDs, and LCAs.

    • Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50, Drugs and Biologicals
    • Check applicable NCDs, LCDs, and LCAs for coverage and claims-payment requirements
    • CMS Medicare Coverage Database: https://www.cms.gov/medicare-coveragedatabase/search.aspx
    Denial Risk

    Safety Exclusions

    Do not approve when the member has severe active central nervous system lupus or an FDA-labeled contraindication to Benlysta.

    • Severe active CNS lupus is an exclusion
    • Any FDA-labeled contraindication to the requested agent is an exclusion
    Denial Risk

    Unmet Clinical Criteria

    Authorization may be denied when required clinical criteria are not met or documentation is insufficient.

    • No qualifying active SLE or active lupus nephritis indication
    • Age is outside FDA labeling without supporting evidence
    • No appropriate specialist prescriber or specialist consultation
    • Required prerequisite therapy, contraindication exception, or concomitant standard therapy is not demonstrated
    • Required lupus-nephritis biopsy, background therapy, Lupkynis sequencing, or combination-therapy evidence is absent
    Denial Risk

    Lack of Renewal Benefit

    Renewal may be denied when the member no longer meets applicable continuation criteria or when clinical benefit from Benlysta is not documented.

    • Required universal or concomitant-therapy criteria are not continued
    • Clinical benefit is absent or not documented
    Billing Rule

    Dose or Administration Limit

    Claims may be denied when billed units exceed the policy’s dose or administration limits for intravenous Benlysta.

    • Loading dose: 116 HCPCS billable units on days 1, 15, and 29
    • Maintenance dose: 116 HCPCS billable units per 28 days
    • Use the labeled loading and maintenance schedules and do not exceed the applicable billable-unit limits
    Billable unit
    HCPCS codeJ0490
    Drug and strengthInjection, belimumab, 10 mg
    Billable unit1 billable unit = 10 mg
    The member does not have severe active central nervous system lupus.
  1. The member does not have any FDA-labeled contraindication to Benlysta.

  2. Qualifying indication pathway

    • Active SLE without active lupus nephritis

      • The member has active systemic lupus erythematosus without active lupus nephritis.

      • Hydroxychloroquine prerequisite

        • The member has tried hydroxychloroquine and had an inadequate response, intolerance, or hypersensitivity.
        • The member has an FDA-labeled contraindication to hydroxychloroquine.

      • Corticosteroid or immunosuppressive prerequisite

        • The member has tried one corticosteroid or immunosuppressive agent and had an inadequate response, intolerance, or hypersensitivity.
        • The member has an FDA-labeled contraindication to all corticosteroids and immunosuppressive agents.
      • The member will continue standard SLE therapy in combination with Benlysta.

        Standard SLE therapy includes corticosteroid, hydroxychloroquine, azathioprine, methotrexate, mycophenolate, or cyclophosphamide.

    • Active lupus nephritis

      • The member has active lupus nephritis.
      • Class III, IV, or V lupus nephritis is confirmed by kidney biopsy.
      • The member will use background immunosuppressive lupus nephritis therapy in combination with Benlysta.

        Examples include corticosteroid plus mycophenolate, azathioprine, or cyclophosphamide.

      • Lupkynis combination requirement

        • Benlysta will not be used in combination with Lupkynis.

        • ALL of the following

          • The member has tried two standard therapy courses and had an inadequate response.

  3. Immunomodulatory combination requirement

    • Benlysta will not be used in combination with another immunomodulatory agent.

    • ALL of the following

      • The prescribing information for Benlysta does not limit its use with another immunomodulatory agent.
      • Support for the combination therapy is submitted.

        Submit clinical trials, phase III studies, or guidelines.

  4. Benlysta will be used in combination with Lupkynis plus mycophenolate.